TABLE 2.
Responses to individual NS3 peptides from pp2 (first four peptides listed) and pp3 (last four peptides listed) that consistently induced IFN-γ-producing cells in at least one of the animals
| Peptide location (aa) | Peptide sequencea | IFN-γ productionb
|
||||
|---|---|---|---|---|---|---|
| Prechallenge
|
Postchallenge
|
|||||
| Vac1 | Vac2 | Vac1 | Vac2 | Ctrl | ||
| 1156 | RPVSYLKGSSGGPLLc | — | <20 | — | — | — |
| 1172 | PSGHVVGIFRAAVCTc | — | — | — | <20 | — |
| 1252 | RVLNPSVAATLGFGAd | — | <20 | <20 | <20 | — |
| 1268 | MSKAHGIEPNIRTGVc | — | — | — | <20 | — |
| 1364 | EVALSNTGEIPFYGKc | — | <20 | — | — | — |
| 1372 | EIPFYGKAIPIEAIK | 20-39 | >40 | — | 20-39 | — |
| 1380 | IPIEAIKGGRHLIFC | 20-39 | 20-39 | — | — | — |
| 1388 | GRHLIFCHSKKKCDEc,d | 20-39 | <20 | — | <20 | — |
The overlapping sequences are underlined.
Results shown are the number of IFN-γ spots per million cells. —, no IFN-γ production detected at week 47 (prechallenge) and week 8 postchallenge. The major histocompatability complex class I typing of the chimpanzees (Patr class I) is as follows: for Vac1, A−, B*0201, C*0601, and A*0601, B*0101, C*0401; for Vac2, A*0401, B*1401, C*0203 and A*1401, B*16011, C*0502; and for the control animal, A*0601, B*0301, C*0901 and A*0401, B*0101, C*0401.
Peptides covering previously described human CD8 epitopes.
Peptides covering previously described human CD4 epitopes.